netFormulary NHS
Pan Mersey
Area Prescribing Committee
 Formulary Chapter 1: Gastrointestinal system - Full Section

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice.

Gastrointestinal system

Review date:July 2021

Non-formulary drugs: Any drug or formulation not listed in the formulary is deemed to be non-formulary.

Off-label use: Drugs are included in the formulary for their licensed indications – where inclusion of off-label use is considered to be included in the formulary this is specifically stated in the formulary entry for the drug N.B. also see Paediatrics note below.

Paediatrics: Drugs are included in the formulary for paediatric use for their BNF for Children recommended indications (indicated by symbol View childrens BNF) which may be off-label, unless otherwise stated. All drugs are deemed to have the same RAG status as they have for adults unless stated otherwise.

NHS England Specialised Commissioning
Drugs carrying the NHS England logo are commissioned by them. Links to key documents, national programmes of care, and clinical reference groups are found below.

NHSE NHS England Specialised Commissioning: Key documents

NHSE NHS England Specialised Commissioning: National programmes of care and clinical reference groups

01.01 Dyspepsia and gastro-oesophageal reflux disease
01.01.01 Antacids and simeticone
01.01.02 Compound alginates and proprietary indigestion preparations
01.02 Antispasmodics and other drugs altering gut motility
Other antispasmodics
Motility stimulants
01.03 Antisecretory drugs and mucosal protectants
Helicobacter pylori infection
01.03.01 H2-receptor antagonists
01.03.02 Selective antimuscarinics
01.03.03 Chelates and complexes
01.03.04 Prostaglandin analogues
01.03.05 Proton pump inhibitors (PPIs)
01.03.06 Other ulcer-healing drugs
01.04 Acute diarrhoea
01.04.01 Adsorbents and bulk-forming drugs
01.04.02 Antimotility drugs
01.04.03 Enkephalinase Inhibitors
01.05 Chronic bowel disorders
01.05.01 Aminosalicylates
01.05.02 Corticosteroids
01.05.03 Drugs affecting the immune response
Cytokine inhibitors
01.05.04 Food allergy
01.06 Laxatives
01.06.01 Bulk-forming laxatives
01.06.02 Stimulant laxatives
01.06.03 Faecal softeners
01.06.04 Osmotic laxatives
01.06.05 Bowel cleansing preparations
01.06.06 Peripheral opiod-receptor antagonist
01.06.07 Other drugs used in constipation
01.07 Local preparations for anal and rectal disorders
01.07.01 Soothing haemorrhoidal preparations
01.07.02 Compound haemorrhoidal preparations with corticosteroids
01.07.03 Rectal sclerosants
01.07.04 Management of anal fissures
01.08 Stoma care
01.09 Drugs affecting intestinal secretions
01.09.01 Drugs affecting biliary composition and flow
Other prepatations for biliary disorders
01.09.02 Bile acid sequestrants
01.09.03 Aprotinin
01.09.04 Pancreatin
01.11 Lactase
01.12 Dysphagia